Loading…
Biologics Price Competition and Innovation Act of 2007
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
99pct
512d open
vs 3,722 other S bills in the 110th — cohort avg 42d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (109)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2010 · second_quarter · Health Issues
State Children's Health Insurance Program (SCHIP)/PL111-3 Managed Care Reform Title VII, PHS act Health Care Reform Appropriate Physician payment levels/systems Medical Records Confidentiality Deficit Reduction Act Children's Access to health insurance Immunizations H.R. 194/S. 958 MediKids Health Insurance Act of 2009 WIC national Immunizations program (administration) The Start Healthy, Stay Healthy Act Immunization Coding Issues Health Care Coverage Expansion and Quality Improvement Act Children's Access to Vision Improvement Act Pandemic Influenza Heath Information Technology/Electronic Health Records HRZ-ARRA Emergency Medical Services for Children' Act Reauthorization Injury Prevention HR 1932/S 999 Child Health Care Crisis Relief Act Preemie Act Pediatrics Disaster Preparedness Education Begins at Home Act Child Maltreatment Foster Care and Adoption Native American Child Health Genetic Nondiscrimination Resident Physician Shortage Reduction Act HR872/S 588 Stem Cell Research Improvement Act HR 881 Mercury Free Vaccines Act HR 2184 Enhanced Health Care Value For All Act HR 2584 High Need Physician Workforce Incentives Act S. 1576 Minority Health Improvement and Health Disparity Elimination Act S. 1695 Biologics Price Competition and Innovation Act HR 1246 Early Hearing and Detection and Intervention Family Smoking Prevention and Tobacco Control Act (PL 111-31) H.R. 3525/S. 467 FACT Act HR1378/S.456 Food Allergy and Anaphylaxis Management Act HR1548Pathway for Biosimilars Act H.R. 4296/S.2408 E-Meds Act HR 1028 Support 21 Act of 2009 S. 726/HR 1427 Promoting Innovation and Access to Life Saving Medicine Act S.819 Autism Treatment Acceleration Act of 2009 HR 1261 Youth Prevention and Tobacco Harm Reduction Act HR 1339 Children's Access to Reconstruction Evaluation and Surgery (CARES)Act S. 1551, Comprehensive TB Elimination Act HR 1210/S. 984 Arthritis Prevention Control and Cure Act of 2009 S.301 Physician Payments Sunshine Act S. 678 Juvenile Justice and Delinquency Prevention Reauthorization Act of 2009 Americans with Disabilities Act National Center on Health Statistics Child Nutrition Reauthorization Needle Exchange Ban National AIDS Strategy HR 1380/S. 1197 Josh Miller HEARTS Act S. 621 Congenital Heart Futures Act Juvenile Justice Accountability and Improvement Act Vaccine Barcoding Pediatric Drugs and Devices HR 3590 The Patient Protection and Affordable Care Act HR 3962 To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes Stop Act Reauthorization Dependent Coverage Tobacco cessation Medicaid coverage Medicaid coverage for juveniles leaving justice system Screening, brief intervention, and referral to treatment for mental health and substance abuse Catastrophic health plans for young adults Insurance discrimination against clinical trial participants Biosimilars and pediatric research Medical home in health reform University autism research Food and Drug Administration Amendments Act (PL 110-85) titles III, IV, V Tanning beds Concussion Treatment and Care Tools Act (H.R. 1347/S. 2840) Smoking in Public Housing Medicaid quitline coverage
Client expense: $56,833 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Consumer Product Safety Commission (CPSC), Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Indian Health Service, Labor, Dept of (DOL), Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Transportation, Dept of (DOT), Treasury, Dept of, White House Office
2010 · first_quarter · Health Issues
HR 1427 and S 726, Promoting Innovation and Access to Life-Saving Medicine Act (Biosimilars) HR 1548, Pathway for Biosimilars Act (Biosimilars) S 1695, Biologics Price Competition and Innovation Act of 2007 (Biosimilars) HR 3590, Patient Protection and Affordable Care Act (Biosimilars) HR 4872, Health Care and Education Reconciliation Act (Biosimilars)
Client expense: $3,070,000 · Firm income: Not reported
2010 · first_quarter · Health Issues
S. 1695, Biologics Price Competition and Innovation Act of 2007 (Biosimilars) HR 3590, Patient Protection and Affordable Care Act (Biosimilars)
Client expense: Not reported · Firm income: $40,000
Government targets: SENATE
2010 · first_quarter · Health Issues
State Children's Health Insurance Program (SCHIP)/PL111-3 Managed Care Reform Title VII, PHS act Appropriate Physician payment levels/systems Medical Records Confidentiality Deficit Reduction Act Children's Access to health insurance Immunizations H.R. 194/S. 958 MediKids Health Insurance Act of 2009 WIC national Immunizations program (administration) The Start Healthy, Stay Healthy Act Immunization Coding Issues Health Care Coverage Expansion and Quality Improvement Act Children's Access to Vision Improvement Act Pandemic Influenza Heath Information Technology/Electronic Health Records HRZ-ARRA Emergency Medical Services for Children' Act Reauthorization Injury Prevention HR 1932/S 999 Child Health Care Crisis Relief Act Preemie Act Pediatrics Disaster Preparedness Education Begins at Home Act Child Maltreatment Foster Care and Adoption Native American Child Health Genetic Nondiscrimination Resident Physician Shortage Reduction Act HR872/S 588 Stem Cell Research Improvement Act HR 881 Mercury Free Vaccines Act HR 2184 Enhanced Health Care Value For All Act HR 2584 High Need Physician Workforce Incentives Act S. 1576 Minority Health Improvement and Health Disparity Elimination Act S. 1695 Biologics Price Competition and Innovation Act HR 1246 Early Hearing and Detection and Intervention Family Smoking Prevention and Tobacco Control Act (PL 111-31) H.R. 3525/S. 467 FACT Act HR1378/S.456 Food Allergy and Anaphylaxis Management Act HR1548Pathway for Biosimilars Act H.R. 4296/S.2408 E-Meds Act HR 1028 Support 21 Act of 2009 S. 726/HR 1427 Promoting Innovation and Access to Life Saving Medicine Act S.819 Autism Treatment Acceleration Act of 2009 HR 1261 Youth Prevention and Tobacco Harm Reduction Act HR 1339 Children's Access to Reconstruction Evaluation and Surgery (CARES)Act S. 1551, Comprehensive TB Elimination Act HR 1210/S. 984 Arthritis Prevention Control and Cure Act of 2009 S.301 Physician Payments Sunshine Act S. 678 Juvenile Justice and Delinquency Prevention Reauthorization Act of 2009 Americans with Disabilities Act National Center on Health Statistics Child Nutrition Reauthorization Needle Exchange Ban National AIDS Strategy HR 1380/S. 1197 Josh Miller HEARTS Act S. 621 Congenital Heart Futures Act Juvenile Justice Accountability and Improvement Act Vaccine Barcoding Pediatric Drugs and Devices HR 3590 The Patient Protection and Affordable Care Act HR 3962 To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes Stop Act Reauthorization Dependent Coverage Tobacco cessation Medicaid coverage Medicaid coverage for juveniles leaving justice system Screening, brief intervention, and referral to treatment for mental health and substance abuse Catastrophic health plans for young adults Insurance discrimination against clinical trial participants Biosimilars and pediatric research Medical home in health reform University autism research Food and Drug Administration Amendments Act (PL 110-85) titles III, IV, V Tanning beds Concussion Treatment and Care Tools Act (H.R. 1347/S. 2840)
2009 · third_quarter · Health Issues
H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548 Pathway for Biosimilars Act S. 1695 Biologics Price Competition and Innovation Act of 2007 Health Care Reform H.R.1346/S.540 Medical Device Safety Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 S.882 Drug and Device Accountability Act of 2009 S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 S. 1679 Affordable Health Choices Act H.R 3200 America's Affordable Health Choices Act of 2009 S. 1796 the Americas Healthy Future Act
Client expense: $770,000 · Firm income: Not reported
| Republican |
| UT |
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $91,142 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Consumer Product Safety Commission (CPSC), Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Indian Health Service, Labor, Dept of (DOL), Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, White House Office
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2009 · fourth_quarter · Health Issues
Patient Protection and Affordable Care Act - H.R.3590; Affordable Health Care for America Act - HR 3962 Biosimilars Follow-on Biologics - Promoting Innovation and Access to Life-Saving Medicine - H.R.1427 Pathway for Biosimilars Act- H.R.1548; Biologics Price Competition and Innovation Act of 2007- S.1695
Client expense: Not reported · Firm income: $110,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Health Issues
Biosimilars H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548, Pathway for Biosimilars Act S. 1695 - Biologics Price Competition and Innovation Act of 2007 H.R. 3200, America's Affordable Health Choices Act of 2009 S. 1679, The Affordable Health Choices Act S. 1796, America's Healthy Future Act of 2009 H.R. 3590, Patient Protection and Affordable Care Act H.R. 3962, Affordable Healthcare for America Act
Client expense: $3,290,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Pharmacy
Issues regarding following biologics, H.R. 5629 Pathway for Biosimilar Act; S. 1695 Biologics, Price Competition and Innovation Act of 2007, H.R. 1956 - provide for approval of similar biological products, H.R. 5629 - establish a pathway for the licensure of biosimilar biological products, H.R. 1038 - provide for licensing of comparable and interchangable biological products, H.R. 3200 and S. 1679.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Pharmacy
Issues regarding follow on bologics, H.R. 5629 Pathway for Biosimilar Act; S. 1695 Biologics, Price Competition and Innovation Act of 2007, H.R. 1956 - provide for approval of similar biological products, H.R. 5629 - establish a pathway for the licensure of biosimilar biological products, H.R. 1038 - provide for licensing of comparable and interchangable biological products, H.R. 3200, S. 1679.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Health Issues
Biosimilars S. 1695, Biologics Price Competition and Innovation Act of 2007 HR 3590, Patient Protection and Affordable Care Act
Client expense: Not reported · Firm income: $60,000
Government targets: SENATE
2009 · fourth_quarter · Health Issues
State Children's Health Insurance Program (SCHIP)/PL111-3 Managed Care Reform Title VII, PHS act Appropriate Physician payment levels/systems Medical Records Confidentiality Deficit Reduction Act Children's Access to health insurance Immunizations H.R. 194/S. 958 MediKids Health Insurance Act of 2009 WIC national Immunizations program (administration) The Start Healthy, Stay Healthy Act Immunization Coding Issues Health Care Coverage Expansion and Quality Improvement Act Children's Access to Vision Improvement Act Pandemic Influenza Heath Information Technology/Electronic Health Records HRZ-ARRA Emergency Medical Services for Children' Act Reauthorization Injury Prevention HR 1932/S 999 Child Health Care Crisis Relief Act Preemie Act Pediatrics Disaster Preparedness Education Begins at Home Act Child Maltreatment Foster Care and Adoption Native American Child Health Genetic Nondiscrimination Resident Physician Shortage Reduction Act HR872/S 588 Stem Cell Research Improvement Act HR 881 Mercury Free Vaccines Act HR 2184 Enhanced Health Care Value For All Act HR 2584 High Need Physician Workforce Incentives Act S. 1576 Minority Health Improvement and Health Disparity Elimination Act S. 1695 Biologics Price Competition and Innovation Act HR 1246 Early Hearing and Detection and Intervention Family Smoking Prevention and Tobacco Control Act (PL 111-31) H.R. 3525/S. 467 FACT Act HR1378/S.456 Food Allergy and Anaphylaxis Management Act HR1548Pathway for Biosimilars Act H.R. 4296/S.2408 E-Meds Act HR 1028 Support 21 Act of 2009 S. 726/HR 1427 Promoting Innovation and Access to Life Saving Medicine Act S.819 Autism Treatment Acceleration Act of 2009 HR 1261 Youth Prevention and Tobacco Harm Reduction Act HR 1339 Children's Access to Reconstruction Evaluation and Surgery (CARES)Act S. 1551, Comprehensive TB Elimination Act HR 1210/S. 984 Arthritis Prevention Control and Cure Act of 2009 S.301 Physician Payments Sunshine Act S. 678 Juvenile Justice and Delinquency Prevention Reauthorization Act of 2009 Americans with Disabilities Act National Center on Health Statistics Child Nutrition Reauthorization Needle Exchange Ban National AIDS Strategy HR 1380/S. 1197 Josh Miller HEARTS Act S. 621 Congenital Heart Futures Act Juvenile Justice Accountability and Improvement Act Vaccine Barcoding Pediatric Drugs and Devices HR 3590 The Patient Protection and Affordable Care Act HR 3962 To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes Stop Act Reauthorization Dependent Coverage Tobacco cessation Medicaid coverage Medicaid coverage for juveniles leaving justice system Screening, brief intervention, and referral to treatment for mental health and substance abuse Catastrophic health plans for young adults Insurance discrimination against clinical trial participants Biosimilars and pediatric research Medical home in health reform University autism research Food and Drug Administration Amendments Act (PL 110-85) titles III, IV, V
Client expense: $74,075 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Consumer Product Safety Commission (CPSC), Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Indian Health Service, Labor, Dept of (DOL), Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, White House Office
2009 · third_quarter · Health Issues
H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548 Pathway for Biosimilars Act S. 1695 Biologics Price Competition and Innovation Act of 2007 Health Care Reform H.R.1346/S.540 Medical Device Safety Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 S.882 Drug and Device Accountability Act of 2009 S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 S. 1679 Affordable Health Choices Act H.R 3200 America's Affordable Health Choices Act of 2009 S. 1796 the Americas Healthy Future Act
Client expense: $750,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2009 · third_quarter · Health Issues
Biosimilars H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548, Pathway for Biosimilars Act S. 1695 - Biologics Price Competition and Innovation Act of 2007 H.R. 3200, America's Affordable Health Choices Act of 2009 S. 1679, The Affordable Health Choices Act S. 1796, America's Healthy Future Act of 2009
Client expense: $3,000,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2009 · third_quarter · Pharmacy
Issues regarding following biologics, HR 5629 Pathway for Biosimilar Act; S 1695 Biologics, Price Competition and Innovation Act of 2007, HR 1956 - provide for approval of similar biological products, HR 5629 - establish a pathway for the licensure of biosimilar biological porducts, HR 1038 - provide for licensing of comparable and interchangeable biological products, HR 3200 and S. 1679.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · third_quarter · Pharmacy
Issues regarding follow on biologics, HR 5629 Pathway for Biosimilar Act; S 1695 Biologics, Price Competition and Innovation Act of 2007, JR 1956 - provide for approval of similar biological products, HR 5629 - establish a pathway for the licensure of biosimilar biological products, HR 1038 - provide for licensing of comparable and interchangeable biological products, HR 3200, S. 1679.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · third_quarter · Health Issues
State Children's Health Insurance Program (SCHIP)/PL111-3 Veto Override Managed Care Reform Title VII, PHS act Appropriate Physician payment levels/systems Medical Records Confidentiality Deficit Reduction Act Children's Access to health insurance Immunizations H.R. 194/S. 958 MediKids Health Insurance Act of 2009 WIC national Immunizations program (administration) The Start Healthy, Stay Healthy Act Immunization Coding Issues Health Care Coverage Expansion and Quality Improvement Act Children's Access to Vision Improvement Act Pandemic Influenza Heath Information Technology/Electronic Health Records HRZ-ARRA Emergency Medical Services for Children' Act Reauthorization Injury Prevention HR 1932/S 999 Child Health Care Crisis Relief Act Preemie Act Pediatrics Disaster Preparedness Education Begins at Home Act Child Maltreatment Foster Care and Adoption Native American Child Health Genetic Nondiscrimination Resident Physician Shortage Reduction Act HR872/S 588 Stem Cell Research Improvement Act HR 881 Mercury Free Vaccines Act HR 2184 Enhanced Health Care Value For All Act HR 2584 High Need Physician Workforce Incentives Act S. 1576 Minority Health Improvement and Health Disparity Elimination Act S. 1695 Biologics Price Competition and Innovation Act HR 1246 Early Hearing and Detection and Intervention Family Smoking Prevention and Tobacco Control Act (PL 111-31) H.R. 3525/S. 467 FACT Act HR1378/S.456 Food Allergy and Anaphylaxis Management Act HR1548Pathway for Biosimilars Act H.R. 4296/S.2408 E-Meds Act HR 1028 Support 21 Act of 2009 S. 726/HR 1427 Promoting Innovation and Access to Life Saving Medicine Act S.819 Autism Treatment Acceleration Act of 2009 S. 579 Federal Tobacco Act of 2009 HR 1261 Youth Prevention and Tobacco Harm Reduction Act HR 1339 Children's Access to Reconstruction Evaluation and Surgery (CARES)Act S. 1551, Comprehensive TB Elimination Act HR 1210/S. 984 Arthritis Prevention Control and Cure Act of 2009 S.301 Physician Payments Sunshine Act S. 678 Juvenile Justice and Delinquency Prevention Reauthorization Act of 2009 H.R. 179 Community AIDS and Hepatitis Prevention Act Americans with Disabilities Act National Center on Health Statistics Child Nutrition Reauthorization Needle Exchange Ban National AIDS Strategy HR 1380/S. 1197 Josh Miller HEARTS Act S. 621 Congential Heart Futures Act Juvenile Justice Accountability and Improvement Act Vaccine Barcoding Pediatric Drugs and Devices
Client expense: $57,797 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Consumer Product Safety Commission (CPSC), Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Indian Health Service, Labor, Dept of (DOL), Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, White House Office
2009 · third_quarter · Health Issues
general healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Follow-on Biologics; Comparative Effectiveness; Comparative Effectiveness Research Act (S.3408); Enhanced Health Care Value for All Act (HR2184); Promoting Innovation and Access to Life-saving Medicine Act (HR1427/S.726); Biologics Price Competition and Innovation Act of 2007 (S.1695); Pathway for Biosimilars Acr (HR1548); Health Reform; America's Affordable Health Choices Act (HR3200); America's Healthy Future Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
Biosimilars H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act HR. 1548, Pathway for Biosimilars Act S. 1695 - Biologics Price Competition and Innovation Act of 2007
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
Biosimilars H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548, Pathway for Biosimilars Act S. 1695 - Biologics Price Competition and Innovation Act of 2007 The Affordable Health Choices Act
Client expense: $3,400,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2009 · second_quarter · Copyright/Patent/Trademark
H.R. 1260/S. 515/S. 610: Patent Reform Act of 2009 (Requested support for the bills) S. 1695: Biologics Price Competition and Innovation Act of 2007 (Requested support for the bill) H.R. 1548: Pathway for Biosimilars Act (Requested support for the bill)
Client expense: $272,724 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
Affordable Health Choice Act. S301 Physician Payments Sunshine Act 2009. HR380, S623, Access to Life-Saving Medicine Act; Follow-on biologics, importation, HR3610 Food and Drug Safety Act of 2007: Import safety; HR5839, Safeguard Americans Pharmaceuticals Act; S2029, Physician's Payment Sunshine Act; Reporting periodicity, pre-emption. HR1427 and HR1038, Access to Life-Saving Medicine Act; follow-on biologics; HR1956, Patient Protection and Innovative Biologic Medicines Act of 2007; follow-on biologics; HR3610, Food and Drug Import Safety Act of 2007; Import safety HR 6151, Responsibilty in Drug and Device Advertising Act of 2008: Direct-to-consumer advertising; S 242, Pharmaceutical Market Acess and Drug Safety Act of 2007: importation; S 334, Healthy Americans Act: non-interference; S. 1693, Wired for Health Care Quality Act: health information technology and health care quality and costs; S 1695, Biologics Price Competition and Innovation Act of 2007: follow-on biologics; S 2663, CPSC Reform Act: importation; S 3398, Medical Device Safety Act of 2008: preemption issues; S 3409, Drug and Device Accountability Act of 2008: import safety
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548 Pathway for Biosimilars Act S. 1695 Biologics Price Competition and Innovation Act of 2007 Health Care Reform H.R. 1616 Early Treatment for HIV Act of 2009 H.R.1346/S.540 Medical Device Safety Act of 2009 Topics related to the safety of medical products Creating a federal program to strengthen awareness, education and treatment of chronic kidney disease H.R.759 Food and Drug Administration Globalization Act of 2009 S.882 Drug and Device Accountability Act of 2009 S.1213/H.R.2502 Patient-Centered Outcomes Research Act of 2009 S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009
Client expense: $700,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2009 · second_quarter · Pharmacy
Access to Life-Saving Medicine Act (H.R. 1038 & S. 623), Affordable Biologics for Consumers Act (S. 1505), Biologics Price Competition and Innovation Act of 2007 (S. 1695), Consumer Food Safety Act of 2008 (H.R. 3624), Fair Prescription Drug Competition Act (H.R. 806 & S. 438), Food and Drug Import Safety Act of 2007 (H.R. 3610, The Pathway for Biologics Act (H.R. 5629), The Patient Protection and Innovative Biologic Medicines Act (H.R. 1956).
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Pharmacy
Issues regarding following biologics, HR 5629 Pathway for Biosimilar Act; S 1695 Biologics, Price Competition and Innovation Act of 2007, HR 1956 - provide for approval of similar biological products, HR 5629 - establish a pathway for the licensure of biosimilar biological porducts, HR 1038 - provide for licensing of comparable and interchangeable biological products.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Pharmacy
Issues regarding follow on biologics, HR 5629 Pathway for Biosimilar Act; S 1695 Biologics, Price Competition and Innovation Act of 2007, JR 1956 - provide for approval of similar biological products, HR 5629 - establish a pathway for the licensure of biosimilar biological products, HR 1038 - provide for licensing of comparable and interchangeable biological products.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation. 3) S. 301-- Advocating for gift disclosure requirements that provide appropriate transparancy and protect proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes; opposed to using such research for cost containment or denial of coverage.
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
general healthcare issues related to pharmaceutical and biological products; Federal, Food Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Follow-on Biologics; Comparative Effectiveness: Comparative Effectiveness Reserach Act (S.3408); Enhanced Health Care Value for All Act (HR2184); Promoting Innovation and Access to Life-saving Medicine Act (HR1427/S.726); Biologics Price Competition and Innovation Act of 2007 (S.1695); Pathway for Biosimilars Act (HR1548); Health Reform; Affordable Health Choices Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
State Children's Health Insurance Program (SCHIP)/PL111-3 Veto Override Managed Care Reform Title VII, PHS act H.R. 2357/S. 2522 MediKids Appropriate Physician payment levels/systems Medical Records Confidentiality Deficit Reduction Act Children's Access to health insurance Immunizations H.R. 194/S. 958 MediKids Health Insurance Act of 2009 WIC national Immunizations program (administration) The Start Healthy, Stay Healthy Act Immunization Coding Issues Health Care Coverage Expansion and Quality Improvement Act Children's Access to Vision Improvement Act Pandemic Influenza Heath Information Technology/Electronic Health Records HRZ-ARRA Emergency Medical Services for Children' Act Reauthorization Injury Prevention HR 1932/S 999 Child Health Care Crisis Relief Act Preemie Act Pediatrics Disaster Preparedness Education Begins at Home Act Child Maltreatment Foster Care and Adoption Native American Child Health Genetic Nondiscrimination Resident Physician Shortage Reduction Act HR872/S 588 Stem Cell Research Improvement Act HR 881 Mercury Free Vaccines Act HR 2184 Enhanced Health Care Value For All Act HR 2584 High Need Physician Workforce Incentives Act S. 1576 Minority Health Improvement and Health Disparity Elimination Act S. 1695 Biologics Price Competition and Innovation Act HR 1246 Early Hearing and Detection and Intervention HR 1256 Family Smoking Prevention and Tobacco Control Act H.R. 3525/S. 467 FACT Act HR1378/S.456 Food Allergy and Anaphylaxis Management Act HR1548Pathway for Biosimilars Act H.R. 4296/S.2408 E-Meds Act HR 1028 Support 21 Act of 2009 S. 726/HR 1427 Promoting Innovation and Access to Life Saving Medicine Act S.819 Autism Treatment Acceleration Act of 2009 S. 579 Federal Tobacco Act of 2009 HR 1261 Youth Prevention and Tobacco Harm Reduction Act HR 1339 Children's Access to Reconstruction Evaluation and Surgery (CARES)Act S. 1551, Comprehensive TB Elimination Act HR 1210/S. 984 Arthritis Prevention Control and Cure Act of 2009 S.301 Physician Payments Sunshine Act S. 678 Juvenile Justice and Delinquency Prevention Reauthorization Act of 2009 H.R. 179 Community AIDS and Hepatitis Prevention Act Americans with Disabilities Act National Center on Health Statistics Child Nutrition Reauthorization Needle Exchange Ban
Client expense: $106,699 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Consumer Product Safety Commission (CPSC), Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Indian Health Service, Labor, Dept of (DOL), Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, White House Office
2009 · first_quarter · Health Issues
Biosimilars H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548, Pathway for Biosimilars Act S. 1695 - Biologics Price Competition and Innovation Act of 2007
Client expense: $2,750,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Health Issues
H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548 Pathway for Biosimilars Act S. 1695 Biologics Price Competition and Innovation Act of 2007 Health Care Reform H.R. 1616 Early Treatment for HIV Act of 2009 H.R.1346/S.540 Medical Device Safety Act of 2009 Topics related to the safety of medical products H.R.759 Food and Drug Administration Globalization Act of 2009 Proposals impacting clinical research
Client expense: $1,260,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2009 · first_quarter · Health Issues
HR 2 Children's Health Insurance Program Reauthorization Act 2009. S301 Physician Payments Sunshine Act 2009. HR380, S623, Access to Life-Saving Medicine Act; Follow-on biologics, importation, HR3610 Food and Drug Safety Act of 2007: Import safety; HR5839, Safeguard Americans Pharmaceuticals Act; S2029, Physician's Payment Sunshine Act; Reporting periodicity, pre-emption. HR1427 and HR1038, Access to Life-Saving Medicine Act; follow-on biologics; HR1956, Patient Protection and Innovative Biologic Medicines Act of 2007; follow-on biologics; HR3610, Food and Drug Import Safety Act of 2007; Import safety HR 6151, Responsibilty in Drug and Device Advertising Act of 2008: Direct-to-consumer advertising; S 242, Pharmaceutical Market Acess and Drug Safety Act of 2007: importation; S 334, Healthy Americans Act: non-interference; S. 1693, Wired for Health Care Quality Act: health information technology and health care quality and costs; S 1695, Biologics Price Competition and Innovation Act of 2007: follow-on biologics; S 2663, CPSC Reform Act: importation; S 3398, Medical Device Safety Act of 2008: preemption issues; S 3409, Drug and Device Accountability Act of 2008: import safety
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Pharmacy
Issues regarding follow on biologics, HR 5629 Pathway for Biosimilar Act; S 1695 Biologics, Price Competition and Innovation Act of 2007, HR 1956 - provide for approval of similar biological products, HR 5629 - establish a pathway for the licensure of biosimilar biological products, HR 1038 - provide for licensing of comparable and interchangeable biological products.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Pharmacy
Issues regarding follow on biologics, HR 5629 Pathway for Biosimilar Act; S 1695 Biologics, Price Competition and Innovation Act of 2007, HR 1956 - provide for approval of similar biological products, HR 5629 - establish a pathway for the licensure of biosimilar biological products, HR 1038 - provide for licensing of comparable and interchangeable biological products.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for reasonable gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
Client expense: $290,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
HR 4703, S 2467, HR 4991 - Vaccine Shortage preparedness Act of 2008 S 2464, HR 4992, HR 4704 - A bill to amend title XVIII of the Social Security Act to provide for coverage of federally recommended vaccines under Medicare Part B S 2465 - Vaccines for Children Access Act of 2008 HR 2 - Children's Health Insurance Program Reauthorization Act of 2009 S 75 - Generics First Act 2009 S 80 - Importation of Prescription Drugs S 301 - Physician Payments Sunshine Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals HR 5839 - Safeguarding America's Pharmaceuticals Act of 2008 S 3408 - Comparative Effectiveness Research Act of 2008 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 S 2467 - Vaccine shortage preparedness Act of 2008 S 3678 - /PL 109-417 All pandemic and all-hazards act - Section 317 program issues HR 970 and S 1378 - Dextromethorphan Distribution Act of 2007 S 103 - Combat Meth Act of 2005 HR 2207 - Agricultural Disaster Assistance and Western States Emergency - Unfinished business Appropriations Act of 2007 HR 1908 and S 1710 Patent Reform Act of 2007 HR 1 - Implementing the 9/11 Commission recommendations Act of 2007 HR 3162 - Children's Health and Medicare Protection Act of 2007 S 1505 - Affordable Biologics for Consumers Act S 1695 - Biologics Price Competition and Innovation Act of 2007 HR 1956 - Patent Protection and Innovative Biologic Medicines Act of 2007 HR 1038, S623 - Access to Life-Saving Medicine Act HR 4083 - Non-prescription Drug Modernization Act of 2007 HR 1308 - Legal Immigrant Children's Health Improvement Act of 2007 HR 5629 - Pathway for Biosimilars Act HR 1427 - To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes S 726 - A bill to amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes Comparative Effectiveness Research Public Health Service Act Drug Importation Gene Therapy Direct to Consumer Advertising Drug Safety Legislation Global Hypertension
Client expense: $1,347,134 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)
2009 · first_quarter · Health Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); FDA Globalization Act (H.R. 759); Follow-on Biologics; Comparative Effectiveness: Comparative Effectiveness Research Ace (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Promoting Innovation and Access to Life-saving Medicine Act (H.R. 1427/S.726); Biologics Price Competition and Innovation Act (S.1695)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Copyright/Patent/Trademark
H.R. 1956, Patent Protection and Innovative Biologic Medicines Act of 2007, S.1695, Biologics Price Competition and Innovation Act of 2007, H.R. 1038, S.623, Access to Life-Saving Medicine Act, H.R. 1908, S.1145, Patent Reform Act of 2007
Client expense: Not reported · Firm income: $6,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
-H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision of mental health and substance-related disorder benefits under group health plans; -H.R. 1494 / S. 830, "Pediatric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediatric medical devices; -H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products; -H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices; -H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids; -H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups; -H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; -H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; -S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; -S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences; -S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank; -S. 558, "Mental Health Parity Act of 2007," regarding all provisions ; -S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities; -S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine; -H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety; -H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production; -H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP; -S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices; -H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services; -H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products; -H.R. 5839, "Safeguarding America's Pharmaceuticals Act of 2008", To Amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs, regarding all provisions; -S. 334, "Healthy Americans Act", A bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away, regarding all provisions; -H.R. 6381, "Medical Device Safety Act of 2008", To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions; -S. 438, "Fair Prescription Drug Competition Act", A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs, regarding all provisions; -S.2274, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan", and for other purposes, regarding all provisions. -S.3409 "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration", and for other purposes; regarding all provisions. -S.1378 "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan", and for other purposes; regarding all provisions. -S. 3408, "Comparative Effectiveness Research Act of 2008", A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes, regarding all provisions; -S. 1276, "Methamphetamine Production Prevention Act of 2008", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions. -Proposed Rule (CMS-1403-P), Regarding revisions to Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions; -S.2424, "A bill to ensure that all Americans have basic health literacy skills to function effectively as patients and health care consumers", regarding all provisions.
Client expense: $1,440,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · third_quarter · Health Issues
Follow-on Biologics - S 1695, HR 1038, HR 1956
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
-H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision of mental health and substance-related disorder benefits under group health plans; -H.R. 1494 / S. 830, "Pediatric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediatric medical devices; -H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products; -H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices; -H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids; -H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups; -H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; -H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; -S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; -S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences; -S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank; -S. 558, "Mental Health Parity Act of 2007," regarding all provisions ; -S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities; -S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine; -H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety; -H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production; -H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP; -S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices; -H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services; -H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products; -H.R. 5839, "Safeguarding America's Pharmaceuticals Act of 2008", To Amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs, regarding all provisions; -S. 334, "Healthy Americans Act", A bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away, regarding all provisions; -H.R. 6381, "Medical Device Safety Act of 2008", To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions; -S. 438, "Fair Prescription Drug Competition Act", A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs, regarding all provisions; -S.2274, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan", and for other purposes, regarding all provisions. -S.3409 "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration", and for other purposes; regarding all provisions. -S.1378 "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan", and for other purposes; regarding all provisions. -S. 3408, "Comparative Effectiveness Research Act of 2008", A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes, regarding all provisions; -S. 1276, "Methamphetamine Production Prevention Act of 2008", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions. -Proposed Rule (CMS-1403-P), Regarding revisions to Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions; -S.2424, "A bill to ensure that all Americans have basic health literacy skills to function effectively as patients and health care consumers", regarding all provisions.
Client expense: $1,440,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · third_quarter · Health Issues
H.R. 5629/S. 1695 Biologics Price Constitution & Innovation Act. Lobbied in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 1424 The Paul Wellstone Mental Health and Addiction Equality Act. Lobbied in support of mental health parity and against increased Medicaid rebates. Labor/HHS Appropriations Bill. Lobbied to ensure patient access to HIV/AIDS medicines through ADAP. S. 2731/H.R. 5501 Tom Lanthos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act. Lobbied in support of reauthorization of the President's Emergency Program for AIDS Relief. H.R. 5839 Safeguarding America's Pharmaceuticals Act. Lobbied to educate about the safety of the prescription drug supply chain. H.R. 3610 Food and Drug Import Safety Act of 2007. Lobbied to ensure safety and access to prescription drugs. S. 999 The STOP Stroke Act. Lobbied for passage of bill. NO BILL, Pharmaceuticals in the environment. Lobbied to educate on the issue of pharmaceuticals in the environment.
Client expense: $840,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · second_quarter · Medicare/Medicaid
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Copyright/Patent/Trademark
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Economics/Economic Development
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Health Issues
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Medical/Disease Research/Clinical Labs
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Medical/Disease Research/Clinical Labs
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Medicare/Medicaid
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Copyright/Patent/Trademark
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)